- Home
- BRKR vs RGEN Comparison
BRKR vs RGEN Comparison
Compare BRKR & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKR
- RGEN
- Stock Information
- Founded
- BRKR 1991
- RGEN 1981
- Country
- BRKR United States
- RGEN United States
- Employees
- BRKR N/A
- RGEN N/A
- Industry
- BRKR Biotechnology: Laboratory Analytical Instruments
- RGEN Medical/Dental Instruments
- Sector
- BRKR Industrials
- RGEN Health Care
- Exchange
- BRKR Nasdaq
- RGEN Nasdaq
- Market Cap
- BRKR 9.9B
- RGEN 8.2B
- IPO Year
- BRKR 2000
- RGEN N/A
- Fundamental
- Price
- BRKR $64.84
- RGEN $141.78
- Analyst Decision
- BRKR Buy
- RGEN Buy
- Analyst Count
- BRKR 10
- RGEN 10
- Target Price
- BRKR $80.11
- RGEN $188.38
- AVG Volume (30 Days)
- BRKR 892.3K
- RGEN 926.2K
- Earning Date
- BRKR 10-31-2024
- RGEN 10-29-2024
- Dividend Yield
- BRKR 0.31%
- RGEN N/A
- EPS Growth
- BRKR 10.49
- RGEN N/A
- EPS
- BRKR 2.39
- RGEN N/A
- Revenue
- BRKR $3,119,700,000.00
- RGEN $602,354,000.00
- Revenue This Year
- BRKR $17.05
- RGEN $0.08
- Revenue Next Year
- BRKR $9.28
- RGEN $12.97
- P/E Ratio
- BRKR $26.75
- RGEN N/A
- Revenue Growth
- BRKR 14.93
- RGEN N/A
- 52 Week Low
- BRKR $53.79
- RGEN $110.45
- 52 Week High
- BRKR $94.86
- RGEN $211.13
- Technical
- Relative Strength Index (RSI)
- BRKR 52.04
- RGEN 43.50
- Support Level
- BRKR $61.74
- RGEN $138.80
- Resistance Level
- BRKR $65.57
- RGEN $150.72
- Average True Range (ATR)
- BRKR 1.96
- RGEN 4.98
- MACD
- BRKR -0.04
- RGEN -0.92
- Stochastic Oscillator
- BRKR 44.44
- RGEN 24.50
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
About RGEN Repligen Corporation
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.